Genentech_ GO40554_Ph1b_II_B cell lymphoma - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn how safe and effective the study drug, mosunetuzumabm, is for treating DLBCL.

What is the Condition Being Studied?

Large B-Cell Lymphoma

Who Can Participate in the Study?

Adults who:
-Have untreated DLBCL
-Have had one chemotherapy course with some response

Age Group
Adults

What is Involved?

If you choose to be in this study you will:
-Be placed in Group A (had treatment for DLBCL) or Group B (never treated before)
-Group A will take the study drug (Mosunetuzumab) into the vein for up to 5 months
-Group B will take the study drug (Mosunetuzumab) into the vein for up to 13 months

Study Details

Full Title
A PHASE I/II TRIAL OF MOSUNETUZUMAB(BTCT4465A) AS CONSOLIDATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FOLLOWING FIRST-LINE IMMUNOCHEMOTHERAPY AND AS THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE UNABLE TO TOLERATE FULL-DOSE CHEMOTHERAPY
Principal Investigator
Cell Therapy and Hematologic Malignancies Specialist
Protocol Number
IRB: PRO00100649
NCT: NCT03677154
Phase
Phase I/II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698